8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A critical analysis of the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, covering enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest concerns.
A detailed breakdown of the SUSTAIN-7 trial's randomization, blinding, estimand framework, comparator dosing, and statistical design, and why each choice matters for interpreting semaglutide vs dulaglutide results.
Deep-dive into cost-effectiveness analyses derived from SUSTAIN-7 data comparing semaglutide vs dulaglutide, including cost per QALY, payer-coverage dynamics, and real-world pricing for patients with type 2 diabetes.
Deep dive into SUSTAIN-7 follow-up and extension data comparing semaglutide vs dulaglutide in type 2 diabetes, examining durability of A1C and weight effects, long-term safety signals, and what the original 40-week trial could not show.
A deep dive into the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, covering primary and secondary endpoint effect sizes, confidence intervals, time-course data, and response distributions.
Deep-dive into SUSTAIN-7 pre-specified and post-hoc subgroup analyses comparing semaglutide vs dulaglutide across age, sex, BMI, baseline A1C, and race in type 2 diabetes.
A deep-dive overview of the SUSTAIN-7 head-to-head RCT comparing semaglutide vs dulaglutide in type 2 diabetes, covering methodology, results, limitations, and clinical practice implications.
A deep-dive into the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, and what its results mean for real-world prescribing decisions today.